A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

Francis J. Giles, Jorge E. Cortes, Hagop M. Kantarjian, Susan M. O'Brien, Elihu Estey, Miloslav Beran

Research output: Contribution to journalArticle

Abstract

As fludarabine, topotecan and cytarabine (ara-C) are effective in acute myeloid leukemia (AML), a pilot study of these three agents combined (FTA) was conducted. FTA consisted of topotecan 1.25mg/m2 by CIV days 1-5, fludarabine 15mg/m2 and ara-C 0.5g/m2 IV, BID, on days 2-6. Seventeen patients (6 primary resistant, 11 relapsed) with AML received 33 courses of FTA. Six patients (35%) achieved complete remission. Seven patients (41%) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML.

Original languageEnglish (US)
Pages (from-to)353-357
Number of pages5
JournalLeukemia Research
Volume28
Issue number4
DOIs
StatePublished - Apr 2004
Externally publishedYes

Fingerprint

Topotecan
Cytarabine
Acute Myeloid Leukemia
Diarrhea
fludarabine

Keywords

  • Acute myeloid leukemia
  • Cytarabine
  • Fludarabine
  • Refractory
  • Topotecan

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. / Giles, Francis J.; Cortes, Jorge E.; Kantarjian, Hagop M.; O'Brien, Susan M.; Estey, Elihu; Beran, Miloslav.

In: Leukemia Research, Vol. 28, No. 4, 04.2004, p. 353-357.

Research output: Contribution to journalArticle

Giles, Francis J. ; Cortes, Jorge E. ; Kantarjian, Hagop M. ; O'Brien, Susan M. ; Estey, Elihu ; Beran, Miloslav. / A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia. In: Leukemia Research. 2004 ; Vol. 28, No. 4. pp. 353-357.
@article{8f80437b88ad4d459a9222d65e7d4250,
title = "A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia",
abstract = "As fludarabine, topotecan and cytarabine (ara-C) are effective in acute myeloid leukemia (AML), a pilot study of these three agents combined (FTA) was conducted. FTA consisted of topotecan 1.25mg/m2 by CIV days 1-5, fludarabine 15mg/m2 and ara-C 0.5g/m2 IV, BID, on days 2-6. Seventeen patients (6 primary resistant, 11 relapsed) with AML received 33 courses of FTA. Six patients (35{\%}) achieved complete remission. Seven patients (41{\%}) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML.",
keywords = "Acute myeloid leukemia, Cytarabine, Fludarabine, Refractory, Topotecan",
author = "Giles, {Francis J.} and Cortes, {Jorge E.} and Kantarjian, {Hagop M.} and O'Brien, {Susan M.} and Elihu Estey and Miloslav Beran",
year = "2004",
month = "4",
doi = "10.1016/j.leukres.2003.08.013",
language = "English (US)",
volume = "28",
pages = "353--357",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia

AU - Giles, Francis J.

AU - Cortes, Jorge E.

AU - Kantarjian, Hagop M.

AU - O'Brien, Susan M.

AU - Estey, Elihu

AU - Beran, Miloslav

PY - 2004/4

Y1 - 2004/4

N2 - As fludarabine, topotecan and cytarabine (ara-C) are effective in acute myeloid leukemia (AML), a pilot study of these three agents combined (FTA) was conducted. FTA consisted of topotecan 1.25mg/m2 by CIV days 1-5, fludarabine 15mg/m2 and ara-C 0.5g/m2 IV, BID, on days 2-6. Seventeen patients (6 primary resistant, 11 relapsed) with AML received 33 courses of FTA. Six patients (35%) achieved complete remission. Seven patients (41%) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML.

AB - As fludarabine, topotecan and cytarabine (ara-C) are effective in acute myeloid leukemia (AML), a pilot study of these three agents combined (FTA) was conducted. FTA consisted of topotecan 1.25mg/m2 by CIV days 1-5, fludarabine 15mg/m2 and ara-C 0.5g/m2 IV, BID, on days 2-6. Seventeen patients (6 primary resistant, 11 relapsed) with AML received 33 courses of FTA. Six patients (35%) achieved complete remission. Seven patients (41%) developed grade 3 or 4 diarrhea. FTA was effective and warrants further study in patients with refractory AML.

KW - Acute myeloid leukemia

KW - Cytarabine

KW - Fludarabine

KW - Refractory

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=1042289343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1042289343&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2003.08.013

DO - 10.1016/j.leukres.2003.08.013

M3 - Article

C2 - 15109534

AN - SCOPUS:1042289343

VL - 28

SP - 353

EP - 357

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 4

ER -